Silverback Therapeutics Inc is a biotechnology business based in the US. Silverback Therapeutics shares (SBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Silverback Therapeutics employs 76 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Active Traders
| Latest market close | $8.65 |
|---|---|
| 52-week range | $8.88 - $63.41 |
| 50-day moving average | $12.04 |
| 200-day moving average | $25.92 |
| Wall St. target price | $45.40 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.23 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.65 from 2021-10-27
| 1 week (2021-10-21) | -6.89% |
|---|---|
| 1 month (2021-09-28) | -19.98% |
| 3 months (2021-07-28) | -71.61% |
| 6 months (2021-04-28) | -75.09% |
| 1 year (2020-10-24) | N/A |
|---|---|
| 2 years (2019-10-24) | N/A |
| 3 years (2018-10-24) | N/A |
| 5 years (2016-10-24) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -10.03% |
| Return on equity TTM | -17.47% |
| Profit margin | 0% |
| Book value | $10.00 |
| Market capitalisation | $322.3 million |
TTM: trailing 12 months
There are currently 4.0 million Silverback Therapeutics shares held short by investors – that's known as Silverback Therapeutics's "short interest". This figure is 9.9% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting Silverback Therapeutics shares can be evaluated.
Silverback Therapeutics's "short interest ratio" (SIR) is the quantity of Silverback Therapeutics shares currently shorted divided by the average quantity of Silverback Therapeutics shares traded daily (recently around 674294.639866). Silverback Therapeutics's SIR currently stands at 5.97. In other words for every 100,000 Silverback Therapeutics shares traded daily on the market, roughly 5970 shares are currently held short.
To gain some more context, you can compare Silverback Therapeutics's short interest ratio against those of similar companies.
However Silverback Therapeutics's short interest can also be evaluated against the total number of Silverback Therapeutics shares, or, against the total number of tradable Silverback Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Silverback Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Silverback Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.228% of the tradable shares (for every 100,000 tradable Silverback Therapeutics shares, roughly 228 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Silverback Therapeutics.
Find out more about how you can short Silverback Therapeutics stock.
We're not expecting Silverback Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Silverback Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read our comprehensive look at NFTs, including what they are, how to invest and the risks attached with buying them.
Everything we know about the Trump Media and Technology Group IPO, plus information on how to buy in.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.